Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS

Publication ,  Conference
Khasraw, M; McDonald, K; Yip, S; Verhaak, R; Heimberger, A; Hall, M; Fisher, L; Barnes, E; Rosenthal, M; Gedye, C; Hovey, E; Ellingson, B ...
Published in: NEURO-ONCOLOGY
November 1, 2018

Duke Scholars

Published In

NEURO-ONCOLOGY

EISSN

1523-5866

ISSN

1522-8517

Publication Date

November 1, 2018

Volume

20

Start / End Page

235 / 235

Location

New Orleans, LA

Publisher

OXFORD UNIV PRESS INC

Conference Name

23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Khasraw, M., McDonald, K., Yip, S., Verhaak, R., Heimberger, A., Hall, M., … Lwin, Z. (2018). NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS. In NEURO-ONCOLOGY (Vol. 20, pp. 235–235). New Orleans, LA: OXFORD UNIV PRESS INC.
Khasraw, Mustafa, Kerrie McDonald, Sonia Yip, Roel Verhaak, Amy Heimberger, Merryn Hall, Lauren Fisher, et al. “NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS.” In NEURO-ONCOLOGY, 20:235–235. OXFORD UNIV PRESS INC, 2018.
Khasraw M, McDonald K, Yip S, Verhaak R, Heimberger A, Hall M, et al. NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. 235–235.
Khasraw M, McDonald K, Yip S, Verhaak R, Heimberger A, Hall M, Fisher L, Barnes E, Rosenthal M, Gedye C, Hovey E, Ellingson B, Simes J, Tognela A, Koh E-S, Gan H, Back M, Lwin Z. NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. 235–235.
Journal cover image

Published In

NEURO-ONCOLOGY

EISSN

1523-5866

ISSN

1522-8517

Publication Date

November 1, 2018

Volume

20

Start / End Page

235 / 235

Location

New Orleans, LA

Publisher

OXFORD UNIV PRESS INC

Conference Name

23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences